20. 8. 94 Official Journal of the European Communities No L 215/21 COMMISSION COMMISSION DECISION of 27 July 1994 on the quantities of controlled substances allowed for essential uses in the Community pursuant to Council Regulation (EEC) No 549/91 on substances that deplete the ozone layer (94/563/EC) THE COMMISSION OF THE EUROPEAN COMMUNITIES, Having regard to the Treaty establishing the European Community, and in particular Article 130a thereof, Having regard to Council Regulation (EEC) No 594/91 of 4 March 1991 on substances that deplete the ozone layer ('), as amended by Regulation (EEC) No 3952/92 (3, Whereas, because of concern for the ozone layer, the Commission has decided to phase out certain controlled substances earlier than stated in the Montreal Protocol, commencing on 1 January 1995; Whereas Regulation (EEC) No 594/91, as amended states the Commission shall determine any essential uses which may be permitted in the Community after 31 December 1994 and any quantities of controlled substances which may be produced, placed on the market or used for their own account by producers for these purposes ; Whereas those essential uses have to be decided for chlo- rofluorocarbons, in accordance with Articles 10 (2) and 11 (2), halons, in accordance with Articles 10 (3) and 11 (3) and carbon tetrachloride, in accordance with Articles 10 (4) and 11 (4) of Regulation (EEC) No 3594/91 ; Whereas the criteria applied to assessing essential uses are in line with Decision IV/25 of the Fourth Meeting of the Parties to the Montreal Protocol and are: (a) that a use of a controlled substance should qualify as ‘essential’ only if : () OJ No L 67, 14. 3. 1991, p. 1. () OJ No L 405, 31. 12. 1992, p. 41. (i) it is necessary for the health, safety or is critical for the functioning of society (encompassing cultural and intellectual aspects); and (ii) there are no available technically and economi- cally feasible alternatives or substitutes that are acceptable from the standpoint of enviroment and health ; (b) that production and consumption, if any, of a controlled substance for essential uses should be permitted only if: (i) all economically feasible steps have been taken to minimize the essential use and associated emission _ of the controlled substance ; and (i) the controlled substance is not available in suffi- cient quantity and quality from existing stocks of banked or recycled controlled substances, also bearing in mind the developing countries’ need for controlled substances ; Whereas after receiving a certain number of applications from Member States, the Commission, assisted by the management committee established pursuant to Article 12 of Regulation (EEC) No 594/91, retained only those limited applications which were considered to meet the essential use criteria in line with the abovementioned Montreal Protocol Decision IV/25; Whereas the identified essential uses fall into four catego- ries, notably : medical uses, solvent uses, laboratory uses . and other uses; whereas the quantitatively most impor- tant essential use is the medical use of MDIs for the Treatment of asthma and other chronic obstructive diseases, as endorsed by the UNEP Technology and Economic Assessment Panel (TEAP) in their March 1994 recommendations to the Parties of the Montreal Protocol ; Whereas this Decision has been taken according to the committee procedure set out in Article 12 of Regulation (EEC) No 594/91, as amended ; ‘